Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F23%3A00013538" target="_blank" >RIV/00023736:_____/23:00013538 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.leukres.2023.107314" target="_blank" >https://doi.org/10.1016/j.leukres.2023.107314</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.leukres.2023.107314" target="_blank" >10.1016/j.leukres.2023.107314</a>

Result language

angličtina

Original language name

Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy

Original language description

Allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients are at high risk of complications associated with COVID-19 infection due to dysfunction of their immune system. Vaccination can protect from the adverse consequences of COVID-19. However, studies on the efficacy of COVID-19 vaccines in HSCT recipients with insufficient post-HSCT immune reconstitution are still scarce. In our study, we determined how immunosuppressive medication and the reconstitution of the cellular immune system influenced T cell responses specific for the surface glycoprotein of SARS-CoV-2 virus (S antigen) after two doses of mRNA vaccine against COVID-19 in patients with myeloid malignancies treated with HSCT.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

<a href="/en/project/NU22-E-138" target="_blank" >NU22-E-138: Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia research

ISSN

0145-2126

e-ISSN

—

Volume of the periodical

130

Issue of the periodical within the volume

July

Country of publishing house

GB - UNITED KINGDOM

Number of pages

9

Pages from-to

"art. no. 107314"

UT code for WoS article

001007162100001

EID of the result in the Scopus database

2-s2.0-85162957330